Answers are grounded in this paper and cite their sources.
Cohort study reveals lower mortality rates in men with bisphosphonates versus denosumab after hip fracture, suggesting treatment differences.
Bisphosphonate users had higher rates of subsequent fracture than denosumab users. Mortality rates in men were lower with bisphosphonates than denosumab. There were no significant differences by dementia and frailty status.
No takes yet. Share an insight, caveat, or question.
Ilomäki et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: